FDA Approves First oral Treatment for rare Glomerulopathy Dr. Kamal Kant Kohli22 March 2025 6:30 AM ISTThe US Food and Drug Administration (FDA) has approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in adults with complement 3...
Novartis oral Fabhalta receives positive EMA Committee opinion for adults with C3 glomerulopathy Ruchika Sharma3 March 2025 10:30 AM ISTBasel: Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...
Novartis bags USFDA accelerated approval for Fabhalta for reduction of proteinuria in primary IgA nephropathy Ruchika Sharma8 Aug 2024 11:30 AM ISTBasel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta (iptacopan), a...
Iptacopan significantly reduce proteinuria in patients with C3 glomerulopathy, reveals APPEAR-C3G trial Dr. Kamal Kant Kohli1 Jun 2024 7:30 AM ISTNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta (iptacopan) at the late-breaking...
Novartis Fabhalta gets positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria Ruchika Sharma24 March 2024 2:30 PM ISTBasel: Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...
FDA approves Fabhalta as oral treatment for paroxysmal nocturnal hemoglobinuria Jacinthlyn Sylvia11 Dec 2023 11:15 AM ISTThe US Food and Drug Administration has approved Fabhalta (iptacopan) as first oral monotherapy for adults suffering from paroxysmal nocturnal...
Novartis gets USFDA nod for Fabhalta for adults with paroxysmal nocturnal hemoglobinuria Ruchika Sharma7 Dec 2023 11:43 AM ISTBasel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Fabhalta (iptacopan) as the first oral monotherapy for the...
